Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 2001 Jul;56(7):529–535. doi: 10.1136/thorax.56.7.529

Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting β2 agonists

H J van der Woude 1, T Winter 1, R Aalbers 1
PMCID: PMC1746085  PMID: 11413351

Abstract

BACKGROUND—In vitro the long acting β2 agonist salmeterol can, in contrast to formoterol, behave as a partial agonist and become a partial antagonist to other β2 agonists. To study this in vivo, the bronchodilating effect of salbutamol was measured during methacholine induced moderate to severe bronchoconstriction in patients receiving maintenance treatment with high dose long acting β2 agonists.
METHODS—A randomised double blind crossover study was performed in 19 asthmatic patients with mean forced expiratory volume in one second (FEV1) of 88.4% predicted and median concentration of methacholine provoking a fall in FEV1 of 20% or more (PC20) of 0.62 mg/ml at entry. One hour after the last dose of 2 weeks of treatment with formoterol (24 µg twice daily by Turbuhaler), salmeterol (100 µg twice daily by Diskhaler), or placebo a methacholine provocation test was performed and continued until there was at least a 30% decrease in FEV1. Salbutamol (50 µg) was administered immediately thereafter, followed by ipratropium bromide (40 µg) after a further 30 minutes. Lung function was monitored for 1 hour after provocation.
RESULTS—There was a significant bronchodilating and bronchoprotective effect after 2 weeks of active treatment. The dose of methacholine needed to provoke a fall in FEV1 of ⩾30% was higher after pretreatment with formoterol (2.48 mg) than with salmeterol (1.58 mg) or placebo (0.74 mg). The difference between formoterol and salmeterol was statistically significant: 0.7 doubling dose steps (95% CI 0.1to 1.2, p=0.016). The immediate bronchodilating effect of subsequently administered salbutamol was significantly impaired after pretreatment with both drugs (p<0.0003 for both). Three minutes after inhaling salbutamol the increase in FEV1 relative to the pre-methacholine baseline was 15.8%, 7.3%, and 5.5% for placebo, formoterol and salmeterol, respectively (equivalent to increases of 26%, 14%, and 12%, respectively, from the lowest FEV1 after methacholine). At 30 minutes significant differences remained, but 1 hour after completing the methacholine challenge FEV1 had returned to baseline values in all three treatment groups.
CONCLUSION—Formoterol has a greater intrinsic activity than salmeterol as a bronchoprotective agent, indicating that salmeterol is a partial agonist compared with formoterol in contracted human airways in vivo. Irrespective of this, prior long term treatment with both long acting β2 agonists reduced the bronchodilating effect of an additional single dose of salbutamol equally, indicating that the development of tolerance or high receptor occupancy overshadowed any possible partial antagonistic activity of salmeterol. Patients on regular treatment with long acting β2 agonists should be made aware that an additional single dose of a short acting β2 agonist may become less effective.



Full Text

The Full Text of this article is available as a PDF (170.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aziz I., Hall I. P., McFarlane L. C., Lipworth B. J. Beta2-adrenoceptor regulation and bronchodilator sensitivity after regular treatment with formoterol in subjects with stable asthma. J Allergy Clin Immunol. 1998 Mar;101(3):337–341. doi: 10.1016/S0091-6749(98)70245-3. [DOI] [PubMed] [Google Scholar]
  2. Aziz I., Lipworth B. J. In vivo effect of albuterol on methacholine-contracted bronchi in conjunction with salmeterol and formoterol. J Allergy Clin Immunol. 1999 May;103(5 Pt 1):816–822. doi: 10.1016/s0091-6749(99)70425-2. [DOI] [PubMed] [Google Scholar]
  3. Cheung D., Timmers M. C., Zwinderman A. H., Bel E. H., Dijkman J. H., Sterk P. J. Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. N Engl J Med. 1992 Oct 22;327(17):1198–1203. doi: 10.1056/NEJM199210223271703. [DOI] [PubMed] [Google Scholar]
  4. Cockcroft D. W., Swystun V. A. Functional antagonism: tolerance produced by inhaled beta 2 agonists. Thorax. 1996 Oct;51(10):1051–1056. doi: 10.1136/thx.51.10.1051. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Fuglsang G., Vikre-Jørgensen J., Agertoft L., Pedersen S. Effect of salmeterol treatment on nitric oxide level in exhaled air and dose-response to terbutaline in children with mild asthma. Pediatr Pulmonol. 1998 May;25(5):314–321. doi: 10.1002/(sici)1099-0496(199805)25:5<314::aid-ppul5>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  6. Grove A., Lipworth B. J. Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients. Lancet. 1995 Jul 22;346(8969):201–206. doi: 10.1016/s0140-6736(95)91265-7. [DOI] [PubMed] [Google Scholar]
  7. Grove A., Lipworth B. J. Effects of prior treatment with salmeterol and formoterol on airway and systemic beta 2 responses to fenoterol. Thorax. 1996 Jun;51(6):585–589. doi: 10.1136/thx.51.6.585. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Grove A., Lipworth B. J. Evaluation of the beta 2 adrenoceptor agonist/antagonist activity of formoterol and salmeterol. Thorax. 1996 Jan;51(1):54–58. doi: 10.1136/thx.51.1.54. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Grove A., Lipworth B. J. Tolerance with beta 2-adrenoceptor agonists: time for reappraisal. Br J Clin Pharmacol. 1995 Feb;39(2):109–118. doi: 10.1111/j.1365-2125.1995.tb04416.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Hancox R. J., Aldridge R. E., Cowan J. O., Flannery E. M., Herbison G. P., McLachlan C. R., Town G. I., Taylor D. R. Tolerance to beta-agonists during acute bronchoconstriction. Eur Respir J. 1999 Aug;14(2):283–287. doi: 10.1034/j.1399-3003.1999.14b08.x. [DOI] [PubMed] [Google Scholar]
  11. Källström B. L., Sjöberg J., Waldeck B. The interaction between salmeterol and beta 2-adrenoceptor agonists with higher efficacy on guinea-pig trachea and human bronchus in vitro. Br J Pharmacol. 1994 Nov;113(3):687–692. doi: 10.1111/j.1476-5381.1994.tb17047.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Langley S. J., Masterson C. M., Batty E. P., Woodcock A. Bronchodilator response to salbutamol after chronic dosing with salmeterol or placebo. Eur Respir J. 1998 May;11(5):1081–1085. doi: 10.1183/09031936.98.11051081. [DOI] [PubMed] [Google Scholar]
  13. Lipworth B. J., Aziz I. A high dose of albuterol does not overcome bronchoprotective subsensitivity in asthmatic subjects receiving regular salmeterol or formoterol. J Allergy Clin Immunol. 1999 Jan;103(1 Pt 1):88–92. doi: 10.1016/s0091-6749(99)70530-0. [DOI] [PubMed] [Google Scholar]
  14. Lipworth B. J., Aziz I. Bronchodilator response to albuterol after regular formoterol and effects of acute corticosteroid administration. Chest. 2000 Jan;117(1):156–162. doi: 10.1378/chest.117.1.156. [DOI] [PubMed] [Google Scholar]
  15. Löfdahl C. G., Andersson L., Bondesson E., Carlsson L. G., Friberg K., Hedner J., Hörnblad Y., Jemsby P., Källén A., Ullman A. Differences in bronchodilating potency of salbutamol in Turbuhaler as compared with a pressurized metered-dose inhaler formulation in patients with reversible airway obstruction. Eur Respir J. 1997 Nov;10(11):2474–2478. doi: 10.1183/09031936.97.10112474. [DOI] [PubMed] [Google Scholar]
  16. Mahadewsingh J. V., Hamersma W. B., Schreurs A. J. Relative efficacy of three different inhalers containing salbutamol in patients with asthma. Eur J Clin Pharmacol. 1996;50(6):467–469. doi: 10.1007/s002280050142. [DOI] [PubMed] [Google Scholar]
  17. Molimard M., Naline E., Zhang Y., Le Gros V., Begaud B., Advenier C. Long- and short-acting beta2 adrenoceptor agonists: interactions in human contracted bronchi. Eur Respir J. 1998 Mar;11(3):583–588. [PubMed] [Google Scholar]
  18. Nelson H. S., Berkowitz R. B., Tinkelman D. A., Emmett A. H., Rickard K. A., Yancey S. W. Lack of subsensitivity to albuterol after treatment with salmeterol in patients with asthma. Am J Respir Crit Care Med. 1999 May;159(5 Pt 1):1556–1561. doi: 10.1164/ajrccm.159.5.9807128. [DOI] [PubMed] [Google Scholar]
  19. Newnham D. M., Grove A., McDevitt D. G., Lipworth B. J. Subsensitivity of bronchodilator and systemic beta 2 adrenoceptor responses after regular twice daily treatment with eformoterol dry powder in asthmatic patients. Thorax. 1995 May;50(5):497–504. doi: 10.1136/thx.50.5.497. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Palmqvist M., Ibsen T., Mellén A., Lötvall J. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am J Respir Crit Care Med. 1999 Jul;160(1):244–249. doi: 10.1164/ajrccm.160.1.9901063. [DOI] [PubMed] [Google Scholar]
  21. Palmqvist M., Persson G., Lazer L., Rosenborg J., Larsson P., Lötvall J. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur Respir J. 1997 Nov;10(11):2484–2489. doi: 10.1183/09031936.97.10112489. [DOI] [PubMed] [Google Scholar]
  22. Politiek M. J., Boorsma M., Aalbers R. Comparison of formoterol, salbutamol and salmeterol in methacholine-induced severe bronchoconstriction. Eur Respir J. 1999 May;13(5):988–992. doi: 10.1034/j.1399-3003.1999.13e10.x. [DOI] [PubMed] [Google Scholar]
  23. Quanjer P. H., Tammeling G. J., Cotes J. E., Pedersen O. F., Peslin R., Yernault J. C. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl. 1993 Mar;16:5–40. [PubMed] [Google Scholar]
  24. Tan K. S., Grove A., McLean A., Gnosspelius Y., Hall I. P., Lipworth B. J. Systemic corticosteriod rapidly reverses bronchodilator subsensitivity induced by formoterol in asthmatic patients. Am J Respir Crit Care Med. 1997 Jul;156(1):28–35. doi: 10.1164/ajrccm.156.1.9610113. [DOI] [PubMed] [Google Scholar]
  25. Wilding P., Clark M., Thompson Coon J., Lewis S., Rushton L., Bennett J., Oborne J., Cooper S., Tattersfield A. E. Effect of long-term treatment with salmeterol on asthma control: a double blind, randomised crossover study. BMJ. 1997 May 17;314(7092):1441–1446. doi: 10.1136/bmj.314.7092.1441. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Yates D. H., Sussman H. S., Shaw M. J., Barnes P. J., Chung K. F. Regular formoterol treatment in mild asthma. Effect on bronchial responsiveness during and after treatment. Am J Respir Crit Care Med. 1995 Oct;152(4 Pt 1):1170–1174. doi: 10.1164/ajrccm.152.4.7551366. [DOI] [PubMed] [Google Scholar]
  27. van Noord J. A., Smeets J. J., Raaijmakers J. A., Bommer A. M., Maesen F. P. Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. Eur Respir J. 1996 Aug;9(8):1684–1688. doi: 10.1183/09031936.96.09081684. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES